Literature DB >> 18852190

Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences.

Guillaume Jean1, Eric Bresson, Jean-Claude Terrat, Thierry Vanel, Jean-Marc Hurot, Christie Lorriaux, Brice Mayor, Charles Chazot.   

Abstract

BACKGROUND: Vascular calcifications (VCs) are frequently observed in chronic kidney disease (CKD) and haemodialysis (HD) patients. They have been associated with numerous factors, particularly hyperphosphataemia, excess calcium load, hypertension and increased mortality rate. The purpose of this study is to measure VCs in long-HD patients with good blood pressure and phosphate control, with the occasional use of sevelamer, using a plain radiological score to identify the associated factors and effects on the 1-year survival rate.
METHODS: We studied HD patients from one centre using a semi-quantitative score ranging from 0 to 3 according to the severity and extent of VCs. The following patients' characteristics were compared according to their VC scores: medical history, treatments, blood pressure, standard biological data, fibroblast growth factor (FGF) 23, osteoprotegerin (OPG), whole PTH, beta-crosslaps, bone alkaline phosphatases and bone mineral density scores. One-year survival analyses were also performed.
RESULTS: Among the 250 HD patients of the centre, 161 were studied; the mean age was 67.2 +/- 13 years, 45% of the subjects were females, 35% were diabetics, and they had been on dialysis for between 1-486 months (median: 45 months) with a 3 x 5-3 x 8 h dialysis schedule using 1.5 mmol/l dialysate calcium and providing a mean 2.25 +/- 0.5 Kt/V. Only 17% of the patients were free from VCs and 11% had severe VCs. The factors associated with VCs were classified into 'classic' (age, diabetes, male gender, tobacco use, inflammation, more frequent warfarin treatment and peripheral vascular and cardiac diseases) and 'non-traditional' (higher FGF-23 and OPG serum levels, low albumin serum levels and low alfacalcidol and CaCO(3) use). In logistic regression, only age, diabetes and FGF-23 serum levels were associated with VC scores of 2 and 3. The patients with a score of 3 had a higher 1-year mortality rate (RR 2.1; P = 0.01) as compared to patients with a 0 score.
CONCLUSION: A plain radiological score showed the high prevalence (83%) of VCs in HD patients in spite of a long and intensive dialysis strategy and adherence to guidelines. The main associated factors were classic factors such as ageing and diabetes. No relationship was found with blood pressure and phosphataemia that remained well controlled in long dialysis; the association with FGF-23 serum levels may aggregate some non-traditional risk factors. The harmful effects of VCs on survival require their systematic assessment and optimization of the potentially modifiable associated factors in CKD and HD patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18852190     DOI: 10.1093/ndt/gfn571

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  74 in total

Review 1.  Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism.

Authors:  L Darryl Quarles
Journal:  Nat Rev Endocrinol       Date:  2012-01-17       Impact factor: 43.330

Review 2.  The role of phosphorus in the development and progression of vascular calcification.

Authors:  Jessica Kendrick; Michel Chonchol
Journal:  Am J Kidney Dis       Date:  2011-09-28       Impact factor: 8.860

Review 3.  Phosphate Toxicity in CKD: The Killer among Us.

Authors:  Cynthia S Ritter; Eduardo Slatopolsky
Journal:  Clin J Am Soc Nephrol       Date:  2016-02-10       Impact factor: 8.237

Review 4.  Noncontrast MR angiography: An update.

Authors:  Robert R Edelman; Ioannis Koktzoglou
Journal:  J Magn Reson Imaging       Date:  2018-12-19       Impact factor: 4.813

Review 5.  Role of FGF23 in vitamin D and phosphate metabolism: implications in chronic kidney disease.

Authors:  L Darryl Quarles
Journal:  Exp Cell Res       Date:  2012-03-07       Impact factor: 3.905

6.  Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease.

Authors:  P Manghat; W D Fraser; A S Wierzbicki; I Fogelman; D J Goldsmith; G Hampson
Journal:  Osteoporos Int       Date:  2009-12-09       Impact factor: 4.507

7.  Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?

Authors:  Rodrigo B Oliveira; Ana L E Cancela; Fabiana G Graciolli; Luciene M Dos Reis; Sérgio A Draibe; Lilian Cuppari; Aluizio B Carvalho; Vanda Jorgetti; Maria E Canziani; Rosa M A Moysés
Journal:  Clin J Am Soc Nephrol       Date:  2009-11-12       Impact factor: 8.237

8.  Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD.

Authors:  James B Wetmore; Shiguang Liu; Ron Krebill; Rochelle Menard; L Darryl Quarles
Journal:  Clin J Am Soc Nephrol       Date:  2009-11-05       Impact factor: 8.237

9.  Atrial fibrillation and low vitamin D levels are associated with severe vascular calcifications in hemodialysis patients.

Authors:  Maria Fusaro; Maurizio Gallieni; Paola Rebora; Maria Antonietta Rizzo; Maria Carmen Luise; Hilary Riva; Silvio Bertoli; Ferruccio Conte; Andrea Stella; Patrizia Ondei; Emanuela Rossi; Maria Grazia Valsecchi; Antonio Santoro; Simonetta Genovesi
Journal:  J Nephrol       Date:  2015-10-22       Impact factor: 3.902

10.  Upregulation of monocyte/macrophage HGFIN (Gpnmb/Osteoactivin) expression in end-stage renal disease.

Authors:  Madeleine V Pahl; Nosratola D Vaziri; Jun Yuan; Sharon G Adler
Journal:  Clin J Am Soc Nephrol       Date:  2009-10-15       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.